Sang Myoung Noh

Title: Innovations of Sang Myoung Noh in Gene Delivery

Introduction

Sang Myoung Noh is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of gene delivery, holding a total of 3 patents. His work focuses on improving the efficiency and stability of gene delivery systems, which are crucial for therapeutic applications.

Latest Patents

One of his latest patents is titled "Composition for gene delivery comprising chitosan and liquid crystal formation material." This invention discloses a composition that forms liquid crystals in an aqueous fluid, utilizing chitosan and a liquid crystal formation material. The composition enhances the binding strength between chitosan and a gene, significantly increasing the stability of the chitosan nanocomposite in blood serum. This advancement allows for highly efficient gene delivery and provides excellent stability, making it a valuable gene therapeutic agent.

Another notable patent is "Composition for gene delivery." This pharmaceutical composition includes a gene, water-soluble chitosan, thiamine pyrophosphate or its pharmaceutically acceptable salt, protamine or its pharmaceutically acceptable salt, and a neutral or anionic phospholipid. The composition is designed to introduce genes into cells safely and effectively. It is composed of non-toxic and injectable components, ensuring safety for the body while achieving high efficiency in gene delivery both in vivo and in vitro.

Career Highlights

Sang Myoung Noh has worked with notable companies such as Chong Kun Dang Pharmaceutical Corporation and Engene, Inc. His experience in these organizations has contributed to his expertise in the field of gene delivery and pharmaceutical innovations.

Collaborations

He has collaborated with several professionals in his field, including Young Nam Lee and Ho Young Hwang. These collaborations have likely enhanced his research and development efforts in gene delivery technologies.

Conclusion

Sang Myoung Noh's innovative work in gene delivery has the potential to significantly impact therapeutic applications. His patents reflect a commitment to advancing the field and improving the efficacy of gene therapies.